Allspring Global Investments’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Allspring Global Investments’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,250	Closed	-$134K	–	2911
2023 Q1	$134K	Sell	1,250 -125	-9%	-$14.4K	﹤0.01%	1935
2022 Q4	$151K	Sell	1,375 -31	-2%	-$2.01K	﹤0.01%	1916
2022 Q3	$82K	Buy	1,406 +933	+197%	+$42.7K	﹤0.01%	2156
2022 Q2	$13K	Sell	473 -5,475	-92%	-$159K	﹤0.01%	2558
2022 Q1	$224K	Sell	5,948 -14	-0.2%	-$553	﹤0.01%	2536
2021 Q4	$235K	Buy	+5,962	New	+$187K	﹤0.01%	2590

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Allspring Global Investments's RXDX Position: Q2 2023 in Review

Allspring Global Investments sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,250 shares — an estimated $134K sold.

Allspring Global Investments first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $235K in Q4 2021. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Allspring Global Investments reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Allspring Global Investments sold 1,250 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $134K.
Allspring Global Investments first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Allspring Global Investments's Prometheus Biosciences, Inc. Common Stock position peaked at $235K in Q4 2021.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Allspring Global Investments's 13F filing for Q2 2023, filed 18 Jul 2023.